Triple Assay of Rectal Mucus in the Diagnosis of Colorectal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

6600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-11-01

Study Completion Date

2027-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Development of a multiomics assay for use on OriColTM sampled rectal mucus for detection of cancer and significant polyps in symptomatic patients on the Colorectal Urgent Suspected Cancer pathway.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.

NCT05102110

Non Small Cell Lung Cancer Pancreatic Cancer Bladder Cancer +1 more

RECRUITING

Exploratory Study of Rectal Mucus for Diagnosing Disease

NCT04659590

Bowel Cancer Bowel Disease Genomic +1 more

COMPLETED

Microbiome Testing for the Screening of Colorectal Cancer

NCT06588166

Colorectal Cancer

RECRUITING

Stool Sample Collection Study

NCT06294873

Colorectal Cancer

RECRUITING

Collection of Blood, Urine, and Stool to Monitor MetastaticColorectal Cancers

NCT03563651

Stage III Colorectal Cancer AJCC v8 Stage IIIA Colorectal Cancer AJCC v8 Stage IIIB Colorectal Cancer AJCC v8 +5 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary objectives of the study are:

1. Confirm the presence of established genetic, epigenetic and microbiome based biomarker signatures associated with CRC and high-risk adenoma (defined as \>10mm in diameter or the presence of high-grade dysplasia) in colorectal urgent suspected cancer referrals, who are triaged for colonoscopy.
2. To expand and refine the genomic, epigenetic and microbiome biomarker signature profiles associated with colorectal cancer and high-risk adenoma to identify rarer biomarkers in addition to those previously established.
3. To generate indicative performance metrics, including an assessment of discriminatory power, sensitivity, specificity and negative predictive values for the clinical application of Oricol™ multiomics assay.

The Secondary Objectives of the study are:

1\. To assess the health economics of delivering a diagnostic service to patients referred to the urgent suspected cancer (USC) pathway via a Community Diagnostic Centre (CDC) in comparison to the current delivery mechanisms through the Two-Week Wait (TWW) pathway.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer Adenoma Colon Polyp

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Oricol Test

Assessment of diagnostic accuracy of Oricol Sampling device for triage in patients with suspected lower gastrointestinal cancer

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients 18 years and over
2. Patients referred from primary care to the 'urgent suspected cancer' CRC pathway during the study period.
3. Patients who provide voluntary written informed consent to participate in the study.

Exclusion Criteria

1. Patients who are unable to undergo digital rectal examination (DRE).
2. Patients with peri-anal/anal symptoms that may limit DRE and proctoscopy examination and it would be clinically inappropriate to attempt to assess these patients. This may include conditions such as:

* Patients who have undergone radiotherapy.
* An acute or chronic anal fissure
* Perianal haematoma
* Acute thrombosed haemorrhoids
* Post- operative anal stenosis
* The presence of an obstructing anal/low rectal tumour or discomfort as a result of previous pelvic radiotherapy
3. Current pregnancy or suspicion of pregnancy.

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No